NORTH CHICAGO, Ill., June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time.A liv ...

The financial media does its best to keep you informed about what’s happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards. That creates an opportunity for investors who have the patience to look for must-own overlooked stocks.  Overlooked stocks are not necessarily underperforming the market. In some cases, these stocks simply are slow and steady at a time when investors want to find the newest and brightest shiny object.  However, not ever ...

文章核心观点 - AbbVie公司的股价在最近一个交易日上涨3.2%,达到161.24美元,这可归因于交易量的显著增加[1] - 这一涨幅是由于公司宣布其重磅免疫药物Skyrizi在溃疡性结肠炎适应症上获得欧洲药品管理局委员会(CHMP)的正面意见[2] - 该公司预计在即将公布的季度财报中,每股收益将同比增长4.8%至3.05美元,但收入将同比下降10.1%至124.6亿美元[3] 行业和公司研究 行业分析 - AbbVie属于大型制药行业,该行业的公司包括强生公司(Johnson & Johnson)[6] - 强生公司最近一个交易日的股价上涨1%,达到146.67美元,但过去一个月下跌3.1%[6] - 强生公司即将公布的季度每股收益预计为2.73美元,同比下降2.5%[7] 公司分析 - AbbVie的Skyrizi药物自上市以来表现出色,得益于在新适应症上的批准[2] - 但AbbVie的季度每股收益预期在过去30天内略有下调,这通常不会带来股价上涨[5] - AbbVie目前的股票评级为中性(Zacks Rank 3)[6]

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement,† were met1,2UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affec ...

文章核心观点 - 公司的增长平台占据了公司业务的约80%,增长率达到中个位数[10] - 公司预计未来几年将实现高个位数的年收入增长[18] - 公司的创新能力和产品组合为其带来了长期的增长机会[15][16][17] 公司概况 - 公司是一家市值275亿美元的制药巨头[8] - 公司自2012年从雅培(Abbott)分拆独立上市以来,每年都在持续增加股息[7] - 公司的主要产品包括Skyrizi和Rinvoq,这两款产品在上市5年内销售额增长超过50%[12][13] - 公司预计这两款产品到2027年的销售额将超过270亿美元,年复合增长率达19%[14] 财务表现 - 公司2023年受到Humira专利到期的影响,预计EPS将下降19%[20] - 但从2024年开始,公司EPS增长预计将恢复到个位数,并在2026年达到12%[20] - 公司当前的市盈率为13.9倍,略高于10年平均水平13.2倍[19] - 结合4%的股息收益率和未来的增长预期,公司预计可以实现8-10%的年化总回报率[21] 发展前景 - 公司正在加强营销力度和战略合作,以更快地提高市场份额[17] - 公司正在积极拓展神经科学和肿瘤科等新领域,为未来发展带来新的增长动力[15][16] - 公司有望凭借创新能力和强大的产品组合,实现未来多年的双位数EPS增长[23]

New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs). Data from the primary analysis of the Phase 2 LUMINOSITY trial evaluating Telisotuzumab ved ...

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower.Let’s get some of the bad stuff out of the way first. Biotech stocks – even the established players – can be volatile. A miss in the clinical process to commercialize a therapeutic could lead to significant losses. And there’s really no way of reliably forecasting such outcomes. Plus, the sector isn’t always known for delivering predictable financial performanc ...

AbbVie's returns haven't been great this year, but investors shouldn't overlook this promising growth stock.Nvidia (NVDA 2.57%) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a high valuation, it sets a high bar for the business and effectively prices in a lot of future growth already. It could make it difficult for the stock to continue to generate high returns. Even if it does, at ...

bunhill Written by Sam Kovacs. Introduction: Does Selling in May make sense? "Sell in May and go away." This Wall Street adage, with roots going back to 18th century England, has somehow endured the test of time. I've always been fascinated by these seasonal shifts and trends in the market. The original phrase was "Sell in May and go away and come back on St. Leger's day." St. Leger's day usually lands somewhere in the middle of September. The idea was that British investors should sell their shares to ...

PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of cancer affecting the pancreas. With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts. A recent report from BioSpa ...